Abstract B051: PDX-derived and patient-derived prostate cancer organoids as a clinically relevant platform for translational research
Michael L. Beshiri(National Cancer Institute), Kathleen Kelly(National Cancer Institute), Eva Corey(University of Washington), Keith H. Jansson(National Cancer Institute), William L. Dahut(National Cancer Institute), Caitlin M. Tice(National Cancer Institute), Adam G. Sowalsky(National Cancer Institute), Kerry M. McGowen(National Cancer Institute), Fatima Karzai(National Institutes of Health), Supreet Agarwal(University of Iowa), Aian Neil Alilin(National Cancer Institute), Holly M. Nguyen(University of Washington), JuanJuan Yin(National Cancer Institute), Crystal Tran(National Cancer Institute)
Cited by 0
Related Papers
Overall Survival Analysis of a Phase II Randomized Controlled Trial of a Poxviral-Based PSA-Targeted Immunotherapy in Metastatic Castration-Resistant Prostate Cancer
|Journal of Clinical Oncology|2010|975
Combining a Recombinant Cancer Vaccine with Standard Definitive Radiotherapy in Patients with Localized Prostate Cancer
|Clinical Cancer Research|2005|371
Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial
|The Lancet Oncology|2012|327
Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations
|Journal for ImmunoTherapy of Cancer|2018|314
Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer
|Cancer Immunology Immunotherapy|2009|298